|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?显示文摘AIM:To investigate the effectiveness of rectally administered indomethacin in the prophylaxis of post-endoscopic retrograde cholangiopancreatography(ERCP)pancreatitis and hyperamylasaemia in a multicentre study.METHODS:A prospective,randomised,placebocontrolled multicentre study in five endoscopic units was conducted on 686 patients randomised to receive a suppository containing 100 mg indomethacin,or an inert placebo,10-15 min before ERCP.Post-ERCP pancreatitis and hyperamylasaemia were evaluated 24 h following the procedure on the basis of clinical signs and laboratory parameters,and computed tomography/magnetic resonance imaging findings if required.RESULTS:Twenty-one patients were excluded because of incompleteness of their data or because of protocol violation.The results of 665 investigations were evaluated:347 in the indomethacin group and 318 in the placebo group.The distributions of the risk factors in the two groups did not differ significantly.Pancreatitis developed in 42 patients(6.3%):it was mild in34(5.1%)and severe in eight(1.2%)cases.Hyperamylaesemia occurred in 160 patients(24.1%).There was no significant difference between the indomethacin and placebo groups in the incidence of either postERCP pancreatitis(5.8%vs 6.9%)or hyperamylasaemia(23.3%vs 24.8%).Similarly,subgroup analysis did not reveal any significant differences between the two groups.CONCLUSION:100 mg rectal indomethacin administered before ERCP did not prove effective in preventing post-ERCP pancreatitis. | Zoltán Dbrnte Zoltán Szepes Ferenc Izbéki Judit Gervain László Lakatos Gyula Pécsi Miklós Ihász Lilla Lakner Erzsébet Toldy László Czakó | 2014 | World Journal of Gastroenterology2014，20，29： | 16 |
| 2 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 3 | Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria显示文摘 | László Gulácsi Alexandru M. Rotar Maciej Niewada Olga L?blová Fanni Rencz Guenka Petrova Imre Boncz Niek S. Klazinga | 2014 | The European Journal of Health Economics2014，，1： | 1 |
| 4 | Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries显示文摘 | László Gulácsi Fanni Rencz Márta Péntek Valentin Brodszky Ruth Lopert Noémi V. Hevér Petra Baji | 2014 | The European Journal of Health Economics2014，，1： | 1 |
| 5 | Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics显示文摘 | Mandel D. Michael Anita Bálint Barbara D. Lovász László Gulácsi Bálint Strbák Petra A. Golovics Klaudia Farkas Zsuzsanna Kürti Blanka K. Szilágyi Anna Mohás Tamás Molnár Péter L. Lakatos | 2014 | The European Journal of Health Economics2014，，1： | 1 |
| 6 | Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries显示文摘 | Márta Péntek Gyula Poór Piotr Wiland Martina Olejárová Marek Brzosko Catalin Codreanu Nóra Brodszky László Gulácsi | 2014 | The European Journal of Health Economics2014，，1： | 1 |
| 7 | In vitro antifungal activity of phenothiazines and their combination with am- photericin B against different Candida species显示文摘 | Galg6czy L B~csi A Homa M | 2011 | Myco- ses2011，54，6： | 1 |
| 8 | Biosimilars for the management of rheumatoid arthritis:economic considerations显示文摘 | Gulácsi L Brodszky V Baji P | 2015 | Expert Rev Clin Immunol2015，11，1： | 1 |
| 9 | Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis显示文摘 | Petra Baji Márta Péntek Sándor Szántó Pál Géher László Gulácsi Orsolya Balogh Valentin Brodszky | 2014 | The European Journal of Health Economics2014，，1： | 1 |
| 10 | AluI polymorphism of the bovine growth hormone(GH)gene,resumption of ovarian cyclicity,milk production and loss of body condition at the onset of lactation in dairy cows显示文摘 | Balogh O Kovács K Kulcsár M Gáspárdy A Zsolnai A Kátai L Pécsi A Fésüs L Butler WR Huszenicza G | | 0，，： | 1 |
| 11 | Pancreatic trophism in experimental liver cirrhosis显示文摘 | István Nagy Ferenc Hajnal Gábor Mohácsi József Németh Zoltán Lászik ákos Pap | 1993 | International Journal of Pancreatology1993，，2： | 1 |
| 12 | Pathways by which interleukin 17 induces articular eartilage breakdown in vitro and vivo显示文摘 | Csi L Yin J P Starovasnik MA | 2001 | Cytokine2001，26，1： | 1 |
| 13 | Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: a 5-year follow-up of a single-center cohort显示文摘 | Gy?ngyvér K?lt? Réka Faludi Dániel Aradi Barbara Bartos Gábor Kumánovics Tünde Minier László Czirják András Komócsi | 2014 | Clinical Rheumatology2014，，2： | 1 |
| 14 | Access to biologicals in Crohn's disease in ten European countries显示文摘AIM To analyze access(availability, affordability and acceptability) to biologicals for Crohn's disease(CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development.METHODS A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals. An availability score was developed to evaluate the restrictiveness of eligibility and administrative criteria applied in the countries. Affordability was defined as the annual cost of treatment as a share of gross domestic product(GDP) per capita. Correlations with the uptake of biologicals, dimensions of access and GDP per capita were calculated.RESULTS At the time of the survey, infliximab and adalimumab were reimbursed in all ten countries, and vedolizumab was reimbursed in five countries(France, Germany, Latvia, Slovakia, Sweden). Reimbursement criteria were the least strict in Sweden and Germany, and the strictest in Hungary, Poland and Slovakia. Between countries, the annual cost of different biological treatments differed 1.6-3.3-fold. Treatments were the most affordable in Sweden(13%-37% of the GDP per capita) and the least affordable in the Central and Eastern European countries, especially in Hungary(87%-124%) and Romania(141%-277%). Biosimilars made treatments more affordable by driving down the annual costs. The number of patients with CD on biologicals per 100000 population was strongly correlated with GDP per capita(0.91), although substantial differences were found in the uptake among countries with similar economic development. Correlation between the number of patients with CD on biologicals per 100000 population and the availability and affordability was also strong(-0.75,-0.69 respectively). CONCLUSION Substantial inequalities in access to biologicals were largely associated with GDP. To explain differences in access among countries with similar development needs further research on acceptance. | Márta Péntek Peter L Lakatos Talitha Oorsprong László Gulácsi Milena Pavlova Wim Groot Fanni Rencz Valentin Brodszky Petra Baji Crohn’s Disease Research Group | 2017 | World Journal of Gastroenterology2017，23，34： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员